

Standing Orders Templates Updated for Administering MenACWY Vaccines to Adults and Children/Teens

Standing orders for other vaccines are available at www.immunize.org/standing-orders.
NOTE: This standing orders template may be adapted per a practice's discretion without obtaining permission from IAC. As a courtesy, please acknowledge IAC as its source.

STANDING ORDERS FOR Administering Meningococcal ACWY Vaccine to Adults

Purpose

To reduce morbidity and mortality from meningococcal disease caused by serotypes A, C, W, or Y by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Policy

Where allowed by state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess the need for and vaccinate adults who meet any of the criteria below.

Procedure

1 Assess adults for need of vaccination against meningococcal disease according to the following criteria:

Routine meningococcal ACWY vaccination

- First-year college students age 19 through 21 years living in a residence hall who were never vaccinated or who were last vaccinated when younger than age 16 years

Risk-based meningococcal ACWY vaccination

- Diagnosis of persistent complement component deficiency (may also be caused by the drug Soliris [eculizumab])
- Diagnosis of anatomic or functional asplenia (including sickle cell disease)
- Diagnosis of human immunodeficiency virus (HIV) infection
- Part of an outbreak attributable to a vaccine serogroup
- Anticipated travel to a country where meningococcal disease is endemic (the "meningitis belt" of sub-Saharan Africa), particularly if contact with the local population will be prolonged
- Employment as a microbiologist with routine exposure to

2 Screen for contraindications and precautions

Contraindications – Do not give MenACWY vaccine to an adult who has had an anaphylactic reaction to a prior dose of the vaccine or to any of its components; refer to the manufacturer's package insert (www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf)

Precaution – Moderate or severe acute illness with or without fever

3 Provide Vaccine Information Statements

Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS) available at www.immunize.org/vis. You must document in the patient's medical record the date of the VIS and the date it was given to the patient. Provide a copy of the VIS in their native language, if one is available and desired; these can be found at www.immunize.org/vis.

4 Review the vaccination schedule and criteria for MenACWY and

For schedule of vaccination of adults with risk factors as identified in the "Meningococcal Vaccination Recommendations by Age and Risk Factor for Adults" found at www.immunize.org/catg.d/p2018.pdf.

IMMUNIZATION ACTION COALITION Saint Paul, Minnesota • 651-647-9009 • www.immunize.org

FOR ADULTS:

www.immunize.org/catg.d/p3081.pdf

FOR CHILDREN/TEENS:

www.immunize.org/catg.d/p3081a.pdf

Download and use these standing orders templates "as they are," or modify them to suit your work setting.

Standing orders for other vaccines are available at www.immunize.org/standing-orders.
NOTE: This standing orders template may be adapted per a practice's discretion without obtaining permission from IAC. As a courtesy, please acknowledge IAC as its source.

STANDING ORDERS FOR Administering Meningococcal ACWY Vaccine to Children and Teens

Purpose

To reduce morbidity and mortality from meningococcal disease caused by serotypes A, C, W, or Y by vaccinating all children and teens who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Policy

Where allowed by state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess the need for and vaccinate children and teens who meet any of the criteria below.

Procedure

1 Assess children and teens for need of vaccination against meningococcal disease according to the following criteria:

Routine meningococcal ACWY vaccination

- Age 11–12 years who have not received MenACWY at age 10 years or older
- As catch-up for ages 13–15 years who have not received MenACWY at age 10 years or older
- Age 16 years and in need of dose #2
- Ages 17 through 18 years and in need of dose #2 as catch-up
- As catch-up for all unvaccinated teens ages 16 through 18 years
- First-year college students age 19 through 21 years living in a residence hall who were never vaccinated or who were last vaccinated when younger than age 16 years

Risk-based meningococcal ACWY vaccination

- Age 2 months and older with diagnosis of persistent complement component deficiency (an immune system disorder, which may also be caused by the drug Soliris [eculizumab]), diagnosis of anatomic or functional asplenia (including sickle-cell disease), or diagnosis of infection with human immunodeficiency virus; children who are part of an outbreak attributable to a vaccine serogroup; or anticipated travel to a country where meningococcal disease is hyperendemic or epidemic (e.g., the "meningitis belt" of sub-Saharan Africa), particularly if contact with the local population will be prolonged

2 Screen for contraindications and precautions

Contraindications – Do not give MenACWY vaccine to a child or teen who has a history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of meningococcal vaccine or to a meningococcal vaccine component. For information on vaccine components, refer to the manufacturer's package insert (www.immunize.org/packageinserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.

Precaution – Moderate or severe acute illness with or without fever

3 Provide Vaccine Information Statements

Provide all patients (or, in the case of a minor, their parent or legal representative) with a copy of the most current federal Vaccine Information Statement (VIS) available at www.immunize.org/vis. You must document in the patient's medical record or office log, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at www.immunize.org/vis.

4 Prepare to Administer Vaccine

Choose the needle gauge, needle length, and injection site according to the following chart:

AGE OF PATIENT	NEEDLE GAUGE	NEEDLE LENGTH	INJECTION SITE
Adolescents (age 11–21 years)	22–25	5/8"–1"	Deltoid muscle of arm
Children (age 3–10 years)	22–25	5/8"–1"	Deltoid muscle of arm
Toddlers (age 1–2 years)	22–25	1–1½"	Anterolateral thigh muscle
Infants (age 2–12 months)	22–25	1"	Anterolateral thigh muscle

* A 5/8" needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle to the skin.

(PAGE 1 OF 2)

IMMUNIZATION ACTION COALITION Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org
www.immunize.org/catg.d/p3081a.pdf • Item #P3081a (12/16)